Novartis is said to be abandoning Ionis heart drug after late-stage trial setback
We haven't written up this one. Seeking Alpha News has the full story — the link below goes straight to it.
More in Finance & Markets
Jodhpur company goes big on Diwali gifts: Four employees get Tata Tiago, Hyundai i20 and Tata Harrier
Mediagarh rewarded four employees with cars during its Diwali celebration in Jodhpur: two Tata Tiagos, a Hyundai i20 and a Tata Harrier.
Choosing Healthcare ETFs: Why IHE Outperforms IBB for Many Investors
Key PointsThe iShares U.S. Pharmaceuticals ETF offers a lower expense ratio and a significantly higher dividend yield than the iShares Biotechnology ETF.
Arista Networks vs. Okta: Which Technology Stock Is a Better Buy for 2027?
Arista's data center dominance meets Okta's identity security in a head-to-head matchup, with a sharp valuation gap that could sway a 2027 portfolio.
- Arista Networks revenue grew to $9.0 billion in 2025, up 28.6% YoY
- Okta reported $2.9 billion revenue in 2026, 11.8% increase YoY
- Okta's stock-based compensation accounts for 61.5% of operating cash flow
Bullion Cues: Supports fuel a rebound
Outlook is positive with dollar remaining a risk